Inspiremd reports fourth quarter and full-year 2023 financial results and provides business update

- record fourth quarter 2023 cguard eps revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - announced positive 30-day data from the company's ongoing u.s. investigational device exemption (ide) clinical trial, c-guardians, designed to support u.s. approval of cguard prime - - named patrick geraghty, m.d. and patrick muck, m.d.
NSPR Ratings Summary
NSPR Quant Ranking